Literature DB >> 30229336

Substantial renal conversion of L-threo-3,4-dihydroxyphenylserine (droxidopa) to norepinephrine in patients with neurogenic orthostatic hypotension.

Guillaume Lamotte1,2, Courtney Holmes3, Patti Sullivan3, David S Goldstein3.   

Abstract

BACKGROUND: The pressor effect of L-threo-3,4-dihydroxyphenylserine (L-DOPS, droxidopa, Northera™) results from conversion of L-DOPS to norepinephrine (NE) in cells expressing L-aromatic-amino-acid decarboxylase (LAAAD). After L-DOPS administration the increase in systemic plasma NE is too small to explain the increase in blood pressure. Renal proximal tubular cells abundantly express LAAAD. Since NE generated locally in the kidneys could contribute to the pressor effect of L-DOPS, in this study we assessed renal conversion of L-DOPS to NE.
METHODS: Ten patients who were taking L-DOPS for symptomatic orthostatic hypotension had blood and urine sampled about 2 h after the last L-DOPS dose. L-DOPS and NE were assayed by alumina extraction followed by liquid chromatography with electrochemical detection. Data were compared in patients off vs. on levodopa/carbidopa.
RESULTS: In patients off levodopa/carbidopa the ratio of NE/L-DOPS in urine averaged 63 times that in plasma (p = 0.0009 by t test applied to log-transformed data). In marked contrast, in the three patients on levodopa/carbidopa the ratio of NE/L-DOPS in urine did not differ from that in plasma.
CONCLUSION: There is extensive renal production of NE from L-DOPS. Carbidopa seems to attenuate the conversion of L-DOPS to NE in the kidneys. Further research is needed to assess whether the proposed paracrine effect of L-DOPS in the kidneys contributes to the systemic pressor response.

Entities:  

Keywords:  Autonomic failure; Dihydroxyphenylserine; Droxidopa; L-DOPS; Norepinephrine; Orthostatic hypotension; Parkinson disease; Parkinsonism; Renal

Year:  2018        PMID: 30229336     DOI: 10.1007/s10286-018-0564-5

Source DB:  PubMed          Journal:  Clin Auton Res        ISSN: 0959-9851            Impact factor:   4.435


  19 in total

1.  Parkinson's disease: the effect of L-dopa therapy on urinary free catecholamines and metabolites.

Authors:  D F Davidson; K Grosset; D Grosset
Journal:  Ann Clin Biochem       Date:  2007-07       Impact factor: 2.057

2.  Contamination of the norepinephrine prodrug droxidopa by dihydroxyphenylacetaldehyde.

Authors:  Courtney Holmes; Noel Whittaker; Jorge Heredia-Moya; David S Goldstein
Journal:  Clin Chem       Date:  2010-03-05       Impact factor: 8.327

Review 3.  The importance of residual kidney function in haemodialysis patients.

Authors:  Jessica Kong; Matthew Davies; Peter Mount
Journal:  Nephrology (Carlton)       Date:  2018-12       Impact factor: 2.506

Review 4.  Catecholamines and their metabolites.

Authors:  B Kågedal; D S Goldstein
Journal:  J Chromatogr       Date:  1988-07-29

5.  Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS.

Authors:  David S Goldstein; Courtney Holmes; LaToya Sewell; Sandra Pechnik; Irwin J Kopin
Journal:  J Clin Pharmacol       Date:  2010-03-10       Impact factor: 3.126

6.  Clinical effects of L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in hemodialysis patients.

Authors:  Tadao Akizawa; Shozo Koshikawa; Nobutoshi Iida; Fumiaki Marumo; Takashi Akiba; Yoshindo Kawaguchi; Akio Imada; Chikao Yamazaki; Masashi Suzuki; Yoshiharu Tubakihara
Journal:  Nephron       Date:  2002-04       Impact factor: 2.847

7.  Norepinephrine precursor therapy in neurogenic orthostatic hypotension.

Authors:  Horacio Kaufmann; Daniela Saadia; Andrei Voustianiouk; David S Goldstein; Courtney Holmes; Melvin D Yahr; Rachel Nardin; Roy Freeman
Journal:  Circulation       Date:  2003-07-28       Impact factor: 29.690

8.  Angiotensin II, independent of plasma renin activity, contributes to the hypertension of autonomic failure.

Authors:  Amy C Arnold; Luis E Okamoto; Alfredo Gamboa; Cyndya Shibao; Satish R Raj; David Robertson; Italo Biaggioni
Journal:  Hypertension       Date:  2012-12-24       Impact factor: 10.190

9.  The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism.

Authors:  J G Nutt; W R Woodward; J L Anderson
Journal:  Ann Neurol       Date:  1985-11       Impact factor: 10.422

10.  Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial.

Authors:  Horacio Kaufmann; Roy Freeman; Italo Biaggioni; Phillip Low; Simon Pedder; L Arthur Hewitt; Joe Mauney; Michael Feirtag; Christopher J Mathias
Journal:  Neurology       Date:  2014-06-18       Impact factor: 9.910

View more
  2 in total

Review 1.  Management of Orthostatic Hypotension.

Authors:  Jose-Alberto Palma; Horacio Kaufmann
Journal:  Continuum (Minneap Minn)       Date:  2020-02

Review 2.  Clinical presentation and long-term follow-up of dopamine beta hydroxylase deficiency.

Authors:  Tessa Wassenberg; Jaap Deinum; Frans J van Ittersum; Erik-Jan Kamsteeg; Maartje Pennings; Marcel M Verbeek; Ron A Wevers; Mirjam E van Albada; Ido P Kema; Jorie Versmissen; Ton van den Meiracker; Jacques W M Lenders; Leo Monnens; Michèl A Willemsen
Journal:  J Inherit Metab Dis       Date:  2020-10-15       Impact factor: 4.982

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.